Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Bioactive Implantable Polymers based on UreidoPyrimidinone

Cel

BIP-UPy addresses the need for biomedical implants which can be easily fine-tuned in their properties in regards to bioactivity, biodegradability, and mechanical performance, and thereby be optimized for their targeted clinical application.
This project will develop a library comprising of a selection of synthetic polymers and specific bioactivities which can be used to provide the required properties for a targeted biomedical implant.
The polymeric materials that will be addressed are supramolecular UPy-modified polymers for uses in urologic implants and embolic implants, benefitting large population groups: bio-degradable meshes with improved in-situ tissue regeneration in pelvic floor repair and endovascular embolic implants with a reduced aneurysm recurrence risk.
A mix-and-match approach will be used to bioactivate these supramolecular base materials. The supramolecular nature of the materials allows for mild processing conditions.
Main objective is to develop a methodology for obtaining implantable polymers with specifically designed bioactivity for in-situ Tissue Engineering, in which the medical implant is obtained in one step by co-processing of the peptide molecules with the neat polymeric material.
Key deliverables are protocols for processable biocompatible UPy-based polymers synthesis and manufacturing scale-up; protocols for UPy-based polymers bioactivity tailoring; procedures for processing the UPy-based polymers preserving the bioactivity efficiency; sterilisation protocols for bioactive medical implants; bioactive implants prototypes with tailored bioactivities; material and implant biocompatibility and bioactivity tests data; new predictive in-vitro tests and drafts of regulatory docs.
BIP-UPy consortium comprises 9 partners from 5 European countries: 3 RTD performing institutions and 2 Hospitals, 3 SMEs and 1 LE representing the strong industrial involvement.
Forth SME (CHEMPILOTS-DK) has whithdrawn from project on 31/12/2014.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP7-NMP-2012-LARGE-6
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-IP - Large-scale integrating project

Koordynator

FUNDACIO EURECAT
Wkład UE
€ 431 479,00
Koszt całkowity
Brak danych

Uczestnicy (10)